CastleVax, a clinical-stage biotechnology company developing intranasal vaccines using its attenuated Newcastle Disease Virus (NDV)-based vaccine platform, announced today that the first participant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback